ClinicalTrials.gg
CompletedNCT06471361Updated Mar 27, 2026Results posted

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

A Phase 3 interventional study of Zilucoplan in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Enrollment
13th of 18
31 · median 45
Started
2024
with 4 others
Phase 3
12 of 18
3 open now
Registered
13th of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 13th largest by enrollment, is one of 5 that started in 2024, is one of 12 in phase 3, and was the 13th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • gMG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant is male or female and must be at least 18 years of age at the time of signing the form (ICF).
  • Study participant must have a documented diagnosis of gMG, based on study participant's history and supported by previous evaluations.
  • Study participant is currently participating in ZLP (zilucoplan) study RA101495-02.302 (NCT04225871) or is administering commercial ZLP on a stable dosing regimen for at least 1 month prior to Screening.
  • Study participants on commercial ZLP need to receive ZLP per the approved local labeling.
  • Study participant is considered reliable and capable of adhering to the study protocol (eg, able to understand and complete questionnaires and able to adhere to the visit schedule) according to the judgement of the Investigator.
  • Study participant is willing and capable of self-administering ZLP using the zilucoplan-auto-injector (ZLP AI) according to the instructions for use (IFU), ie, does not have any visual, physical, or other disability or impairment that interferes with his/her capacity to self-administer; if the participant has a caregiver, he/she may assist the participant with the injection.
  • Vaccination with a quadrivalent meningococcal vaccine and, where available, meningococcal serotype B vaccine at least 14 days prior to medicinal product (IMP) administration, if not vaccinated within 3 years prior to the start of treatment. Booster vaccination(s) should also be administered as clinically indicated, according to the local standard of care, for participants who have been previously vaccinated against Neisseria meningitidis.
  • Female participants of must have a negative urine pregnancy test prior to the first dose of study drug.
  • Male and/or female study participants

    1. A male participant must agree to use during the Treatment Period and for 40 days after the last dose of study medication, and refrain from donating sperm during this period.
    2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
  • Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance the Treatment Period and for 40 days after the last dose of study medication.
  • Capable of giving signed informed which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.
  • Female participants who are breastfeeding, pregnant, or plan to become pregnant during the study.
  • Study participant has a known to any components of the study medication (and/or an device) as stated in this protocol.
  • Study participant has a active infection or a history of serious infection (resulting in hospitalization or requiring intravenous antibiotic treatment) within 6 weeks before Visit 1.
  • Study participant has a history of meningococcal disease.
  • Participant has previously participated in this study or participant has previously been assigned to treatment in a study of the medication under investigation in this study (except studies RA101495-02.201 (NCT03315130), RA101495-02.301 (NCT04115293), or RA101495-02.302 (NCT04225871), which are not excluded, unless the participant was required to withdraw from said studies for a safety reason which could reasonably recur).
  • Participant has participated in another study of an IMP (and/or an investigational device) different from ZLP within the previous 3 months or 5 half-lives, whichever is longer, or is currently participating in another study of an IMP (and/or an investigational device).
  • Current unstable liver or biliary disease at Screening (Visit 1), per Investigator assessment, defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: with exception of stable hepatobiliary conditions (including Gilbert's syndrome, asymptomatic gallstones).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Zilucoplan-auto-injector (ZLP-AI)

    Study participants will self-administer zilucoplan (ZLP) based on their body weight using auto-injector (AI).

    Drug: Zilucoplan

Interventions

  • Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

    Also known as: RA101495

06

What researchers measure

Primary outcomes

  1. Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8

    Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of investigational medicinal product (IMP) was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the Safety Set (SS). Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

    Time frame: From Visit 1 (Day 1) to Visit 8 (Day 14)

Secondary outcomes

  1. Percentage of Effective Self-administration of Zilucoplan Using ZLP-AI at Visit 1

    Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of IMP was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the SS. Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

    Time frame: Visit 1 (Day 1)

  2. Percentage of Effective Self-administrations of Zilucoplan Using ZLP-AI at Visit 8

    Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of IMP was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the SS. Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

    Time frame: Visit 8 (Day 14)

  3. Percentage of Participants With Serious Adverse Events (SAEs) During the Course of the Study

    An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: Led to death; Led to a life-threatening illness or injury; Led to a permanent impairment of a body structure or a body function; Led to a inpatient or prolonged hospitalization; Led to a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; Led to fetal distress, fetal death, or a congenital abnormality or birth defect.

    Time frame: From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)

  4. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Course of the Study

    An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. A TEAE was defined as an AE starting on or after the date/time of the first self-injection of ZLP-AI and up to and including 40 days after the final self-injection of ZLP-AI (or last contact depending on which occurs first).

    Time frame: From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)

  5. Percentage of Participants With Non-serious Adverse Device Effects (ADE) During the Course of the Study

    An ADE was defined as an AE related to the use of an investigational medical device included any AEs resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device as well as any event resulting from use error or from intentional misuse of the investigational medical device.

    Time frame: From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)

  6. Percentage of Participants With Serious Adverse Device Effects (SADE) During the Course of the Study

    An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: Led to death; Led to a life-threatening illness or injury; Led to a permanent impairment of a body structure or a body function; Led to a inpatient or prolonged hospitalization; Led to a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; Led to fetal distress, fetal death, or a congenital abnormality or birth defect. A SADE was defined as an adverse device effect that had resulted in any of the consequences characteristic of a SAE.

    Time frame: From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)

07

Results

Posted Mar 27, 2026

Participant flow

The study started to enroll participants in August 2024 and concluded in February 2025.

Participant flow — Overall Study
MilestoneZilucoplan
Started31
Completed31
Not completed0

Outcome measures

PrimaryPercentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8

Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of investigational medicinal product (IMP) was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the Safety Set (SS). Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

Time frame:
From Visit 1 (Day 1) to Visit 8 (Day 14)
Reported as:
Number · Percentage of ZLP-AI devices
Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8
Percentage of ZLP-AI devicesZilucoplan
Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 899.8 (98.8 to 100.0)
SecondaryPercentage of Effective Self-administration of Zilucoplan Using ZLP-AI at Visit 1

Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of IMP was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the SS. Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

Time frame:
Visit 1 (Day 1)
Reported as:
Number · Percentage of ZLP-AI devices
Percentage of Effective Self-administration of Zilucoplan Using ZLP-AI at Visit 1
Percentage of ZLP-AI devicesZilucoplan
Percentage of Effective Self-administration of Zilucoplan Using ZLP-AI at Visit 196.9 (83.8 to 99.9)
SecondaryPercentage of Effective Self-administrations of Zilucoplan Using ZLP-AI at Visit 8

Effective SA of ZLP was defined as completeness of the delivery as confirmed by the Investigator. The entire dose of IMP was completely delivered (ie, the yellow plunger that was seen through the device window was completely depressed). The percentage of effective SA overall was summarized based on the number of ZLP-AIs used and returned, within participants in the SS. Complete Dose Delivery = Total number (no.) of ZLP-AIs with complete dose delivery/Total no. of ZLP-AIs used and returned.

Time frame:
Visit 8 (Day 14)
Reported as:
Number · Percentage of ZLP-AI devices
Percentage of Effective Self-administrations of Zilucoplan Using ZLP-AI at Visit 8
Percentage of ZLP-AI devicesZilucoplan
Percentage of Effective Self-administrations of Zilucoplan Using ZLP-AI at Visit 8100.0 (87.7 to 100.0)
SecondaryPercentage of Participants With Serious Adverse Events (SAEs) During the Course of the Study

An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: Led to death; Led to a life-threatening illness or injury; Led to a permanent impairment of a body structure or a body function; Led to a inpatient or prolonged hospitalization; Led to a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; Led to fetal distress, fetal death, or a congenital abnormality or birth defect.

Time frame:
From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) During the Course of the Study
percentage of participantsZilucoplan
Percentage of Participants With Serious Adverse Events (SAEs) During the Course of the Study0
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Course of the Study

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. A TEAE was defined as an AE starting on or after the date/time of the first self-injection of ZLP-AI and up to and including 40 days after the final self-injection of ZLP-AI (or last contact depending on which occurs first).

Time frame:
From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Course of the Study
percentage of participantsZilucoplan
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Course of the Study22.6
SecondaryPercentage of Participants With Non-serious Adverse Device Effects (ADE) During the Course of the Study

An ADE was defined as an AE related to the use of an investigational medical device included any AEs resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device as well as any event resulting from use error or from intentional misuse of the investigational medical device.

Time frame:
From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-serious Adverse Device Effects (ADE) During the Course of the Study
percentage of participantsZilucoplan
Percentage of Participants With Non-serious Adverse Device Effects (ADE) During the Course of the Study3.2
SecondaryPercentage of Participants With Serious Adverse Device Effects (SADE) During the Course of the Study

An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: Led to death; Led to a life-threatening illness or injury; Led to a permanent impairment of a body structure or a body function; Led to a inpatient or prolonged hospitalization; Led to a medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; Led to fetal distress, fetal death, or a congenital abnormality or birth defect. A SADE was defined as an adverse device effect that had resulted in any of the consequences characteristic of a SAE.

Time frame:
From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Device Effects (SADE) During the Course of the Study
percentage of participantsZilucoplan
Percentage of Participants With Serious Adverse Device Effects (SADE) During the Course of the Study0

Adverse events

Collected over From Visit 1 (Day 1) up to 40 days after last administration of self-injection of ZLP-AI (up to 54 days after Visit 1). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilucoplan0/31 (0%)0/31 (0%)3/31 (9.7%)
Most frequent other events
Most frequent other events
EventZilucoplan
Injection site painGeneral disorders3/31

Baseline characteristics

Baseline refers safety set (SS) which consisted of all study participants in the study who received at least 1 dose of ZLP with the ZLP-AI combination product.

Age, Continuous
Age, Continuous(years)Zilucoplan
Mean61.4 ± 11.7
Age, Customized
Age, Customized(Participants)Zilucoplan
18 - <65 years15
65 - <8516
>=85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Zilucoplan
Female12
Male19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zilucoplan
Asian1
Black or African American3
White25
Other or Mixed2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zilucoplan
Hispanic or Latino1
Not Hispanic or Latino30
08

Study locations

11 sites
  • Dv0013 50628
    New Haven, Connecticut 06511, United States
  • Dv0013 50634
    Tampa, Florida 33612, United States
  • Dv0013 50648
    Columbia, Missouri 64212, United States
  • Dv0013 50556
    Chapel Hill, North Carolina 27599, United States
  • Dv0013 50635
    Columbus, Ohio 43221, United States
  • Dv0013 50555
    Austin, Texas 78759, United States
  • Dv0013 50636
    Greenfield, Wisconsin 53228, United States
  • Dv0013 40609
    Katowice, Poland
  • Dv0013 40759
    Krakow, Poland
  • Dv0013 40605
    Poznan, Poland
  • Dv0013 40760
    Oxford, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jan 2025, 5 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 5 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jun 24, 2024
StartActual
Aug 27, 2024
Primary completionActual
Jan 28, 2025
CompletionActual
Feb 3, 2025
Results first posted
Mar 27, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06471361
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Aug 27, 2024
Primary completion
Jan 28, 2025
Completion
Feb 3, 2025
Results posted
Mar 27, 2026
Last update
Mar 27, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion